These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 3037813)

  • 1. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus.
    Okuno Y; Okamoto Y; Yamada A; Baba K; Yabuuchi H
    Vaccine; 1987 Jun; 5(2):128-32. PubMed ID: 3037813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibody responses to Japanese encephalitis vaccine in children.
    Juang RF; Okuno Y; Fukunaga T; Tadano M; Fukai K; Baba K; Tsuda N; Yamada A; Yabuuchi H
    Biken J; 1983 Mar; 26(1):25-34. PubMed ID: 6626137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody responses to Japanese encephalitis vaccine in children.
    Juang RF; Fukai K
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1983 Sep; 16(3):190-7. PubMed ID: 6680096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases.
    Yamada A; Imanishi J; Juang RF; Fukunaga T; Okuno Y; Tadano M; Fukai K; Baba K; Yabuuchi H
    Vaccine; 1986 Mar; 4(1):32-4. PubMed ID: 3008460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains.
    Kurane I; Takasaki T
    Vaccine; 2000 May; 18 Suppl 2():33-5. PubMed ID: 10821971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.
    Ku CC; King CC; Lin CY; Hsu HC; Chen LY; Yueh YY; Chang GJ
    J Med Virol; 1994 Oct; 44(2):122-31. PubMed ID: 7852952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
    Konishi E; Yamaoka M; Kurane I; Mason PW
    Virology; 2000 Mar; 268(1):49-55. PubMed ID: 10683326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune status of volunteers one year after administration of Japanese encephalitis vaccine produced in India.
    Saxena SN; Bhau LN; Singh G; Gowal D; Sood YK; Misra CN; Das BK
    Indian J Med Res; 1989 Nov; 89():362-7. PubMed ID: 2559892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas].
    Zhou B; Jia L; Xu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.
    Ferguson M; Johnes S; Li L; Heath A; Barrett A
    Biologicals; 2008 Mar; 36(2):111-6. PubMed ID: 17892945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological and ecological studies of Japanese encephalitis in Okinawa, subtropical area in Japan. II. Prevalence of Japanese encephalitis antibody in residents in Okinawa, Miyako and Ishigaki islands.
    Tadano M; Kanemura K; Arakaki S; Makino Y; Fukunaga T; Hokama T; Kyan T; Makiya H; Taira Y; Ohama N
    Microbiol Immunol; 1994; 38(2):123-8. PubMed ID: 8041299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of neutralizing antibodies elicited by a vaccine (Nakayama) strain of Japanese encephalitis virus in Taiwan.
    Shyu WR; Wang YC; Chin C; Chen WJ
    Epidemiol Infect; 1997 Aug; 119(1):79-83. PubMed ID: 9287947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.